Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
801 to 820 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. | Cancers (Basel) | 2022 | 35740550 | PubTator, text mining | PubMed |
| Electroporation and Immunotherapy-Unleashing the Abscopal Effect. | Cancers (Basel) | 2022 | 35740542 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma. | Front Genet | 2022 | 35734424 | PubTator, text mining | PubMed |
| Silencing of B7-H4 induces intracellular oxidative stress and inhibits cell viability of breast cancer cells via downregulating PRDX3. | Neoplasma | 2022 | 35723197 | PubTator, text mining | PubMed |
| B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. | Eur J Cancer | 2022 | 35717821 | PubTator, text mining | PubMed |
| Transcriptome-Wide m6A Methylome and m6A-Modified Gene Analysis in Asthma. | Front Cell Dev Biol | 2022 | 35712670 | PubTator, text mining | PubMed |
| The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma. | Front Cell Dev Biol | 2022 | 35712653 | PubTator, text mining | PubMed |
| A Potential Role of B7-H4 Expression in Predicting the Recurrence of Chronic Rhinosinusitis with Nasal Polyps. | J Inflamm Res | 2022 | 35711239 | PubTator, text mining | PubMed |
| Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation. | BMC Biol | 2022 | 35705990 | PubTator, text mining | PubMed |
Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. | Front Immunol | 2022 | 35693827 | PubTator, text mining | PubMed |
| SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma. | Front Genet | 2022 | 35692837 | PubTator, text mining | PubMed |
| Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases. | Front Oncol | 2022 | 35692807 | PubTator, text mining | PubMed |
| Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration. | J Immunol Res | 2022 | 35692505 | PubTator, text mining | PubMed |
| CT Features of Stage IA Invasive Mucinous Adenocarcinoma of the Lung and Establishment of a Prediction Model. | Int J Gen Med | 2022 | 35692354 | PubTator, text mining | PubMed |
| The immune landscape of solid pediatric tumors. | J Exp Clin Cancer Res | 2022 | 35690832 | PubTator, text mining | PubMed |
| Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. | Molecules | 2022 | 35684481 | PubTator, text mining | PubMed |
| Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review. | Int J Mol Sci | 2022 | 35682714 | PubTator, text mining | PubMed |
| Development of a Prognostic Model Based on Pyroptosis-Related Genes in Pancreatic Adenocarcinoma. | Dis Markers | 2022 | 35677632 | PubTator, text mining | PubMed |
| Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma. | J Immunol Res | 2022 | 35677537 | PubTator, text mining | PubMed |
| Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2022 | 35675036 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=41